Literature DB >> 3332855

Haematological classification of the chronic myeloid leukaemias.

P C Shepherd, T S Ganesan, D A Galton.   

Abstract

Chronic myeloid leukaemia (CML) includes five subtypes, and the term should be used in the same way as the term chronic lymphoid leukaemia to refer to a group of related conditions. The subtypes of CML are: 1. Chronic granulocytic leukaemia (CGL) (95% of all CML; 90% are Ph+, BCR+, 5% are Ph-, BCR+); 2. Juvenile CML (extremely rare; Ph-, BCR- in the few so far examined); 3. Chronic neutrophilic leukaemia (CNL) (extremely rare; Ph-, BCR- in the few so far examined); 4. Chronic myelomonocytic leukaemia (CMML). CMML with low or normal leukocyte counts is classified as a myelodysplastic syndrome; CMML with high leukocyte count is both myelodysplastic and myeloproliferative. Ph-, BCR-; 5. Atypical CML (aCML). Intermediate between CGL and CMML but has distinctive features. Ph-, mostly BCR-. Significance of few reported BCR+ uncertain. Markedly worse survival than CGL and probably worse than CMML. Definition needs refining. Types 2, 3, 4 and 5 account for 5% of all CML. CGL, CMML, aCML and CNL can be diagnosed in the great majority of cases from the morphological profile of presentation peripheral blood films, but high-quality Romanowsky staining is essential.

Entities:  

Mesh:

Year:  1987        PMID: 3332855     DOI: 10.1016/s0950-3536(87)80031-8

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  3 in total

Review 1.  Routine and specialised techniques in the diagnosis of haematological neoplasms.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

2.  Further evidence for the molecular heterogeneity of chronic myeloid leukemia.

Authors:  A Hernandez; L Corral; A Muñiz; C Alaez; E Espinosa; G Martinez; P Hernandez
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

3.  bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

Authors:  A G Elefanty; I K Hariharan; S Cory
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.